Nanoformulations for combination or cascade anticancer therapy

Miao, Lei; Guo, Shutao; Lin, Cuiying; Liu, Qi; Huang, Leaf

doi:10.1016/j.addr.2017.06.003

Cited by 148 publications

(91 citation statements)

References 230 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7][8][9] Drugs' nanoformulations have been extensively developed and used for cancer therapy if approved by the Food and Drug Administration (FDA), leading to effective anticancer potential with less toxicity. 10 Nanoparticles (NPs) such as carbon, ceramic, chitosan, and poly(lactic-co-glycolic acid) (PLGA) NPs have been extensively used for drug delivery enhancement. 11,12 PLGA NPs are biocompatible, biodegradable, and stable in biological fluids, protect the loaded compounds from degradation, and provide their sustained release.…”

Section: Introductionmentioning

confidence: 99%

<p>Nanoformulated Bioactive Compounds Derived from Different Natural Products Combat Pancreatic Cancer Cell Proliferation</p>

Mousa¹,

El‐Far²,

Saddiq³

et al. 2020

IJN

View full text Add to dashboard Cite

This study was designed to determine the potential effect of nanoencapsulated bioactive compounds from different natural sources on human pancreatic cancer. Background: Pancreatic cancer carries the highest fatality rate among all human cancers because of its high metastatic potential and late presentation at the time of diagnosis. Hence there is a need for improved methods to prevent and treat it. Natural products, such as 3, 3′diindolylmethane (DIM) and ellagic acid (EA) demonstrated anticancer efficacy against various cancer types. However, DIM is insoluble. Hence, using nanotechnology to encapsulate these compounds in combination with EA might improve their physical and chemical properties and their delivery to the cancer cells. Methods: Human pancreatic cancer cells, namely SUIT2-luciferase transfected, were used to examine the effects of DIM or EA and their nanoformulation in poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) [PLGA-PEG] nanoparticles (NPs) on SUIT2luciferase cell viability/proliferation over 24 hrs. Additionally, effects on tumor weight and angiogenesis were determined using the chick chorioallantoic membrane (CAM) tumor implant model. Results: Both DIM and EA PLGA-PEG NPs resulted in rapid suppression of pancreatic cancer cell viability/proliferation within 24 hrs (P < 0.01), while the non-encapsulated DIM and EA did not show any significant effect on SUIT2 cancer cell viability or cell proliferation (MTT assay). In the CAM pancreatic cancer cell (SUIT2) implant model, results showed a greater suppression of tumor weight (P < 0.01), tumor cell viability, and tumor angiogenesis (P < 0.01) for DIM NPs and EA NPs and their combinations versus DIM or EA alone. Conclusion: Nanoformulation of DIM and EA resulted in a more effective suppression of pancreatic cancer cell viability, pancreatic tumor weight, implanted cancer cell viability, and tumor angiogenesis as compared with these bioactive compounds alone.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Nanoformulated Bioactive Compounds Derived from Different Natural Products Combat Pancreatic Cancer Cell Proliferation</p>

Mousa¹,

El‐Far²,

Saddiq³

et al. 2020

IJN

View full text Add to dashboard Cite

show abstract

“…Advances in nanocarriers have supported remarkable opportunities in combination chemotherapy. Many nanoplatforms have been used for drug delivery [42]. In our previous study, a kind of CSaSt was prepared.…”

Section: Preparation and Characterization Of Dds Npsmentioning

confidence: 99%

Doxorubicin and ABT-199 Coencapsulated Nanocarriers for Targeted Delivery and Synergistic Treatment against Hepatocellular Carcinoma

Zhou

Fan

et al. 2019

Journal of Nanomaterials

View full text Add to dashboard Cite

For the patients with hepatocellular carcinoma (HCC), conventional chemotherapy is insufficient or has no benefit. Although combination chemotherapy has been proven as an efficient strategy to enhance anti-HCC efficacy, some barriers, such as low bioavailability and side effects, are limiting clinical development. In order to overcome disadvantages of combination chemotherapy in HCC, targeted nanoparticles (NPs) simultaneously loaded with doxorubicin (DOX) and ABT-199 in an optimal synergistic ratio were developed. First, the most synergistic combination with DOX was screened from ABT-199, ABT-263, and ABT-737. Among them, ABT-199 showed optimal synergy with DOX in a ratio of 10 : 1. Then, cationic amphipathic starch (CSaSt) and hyaluronic acid (HA) were used in coencapsulations of those two drugs. Dual-drug synergistic nanoparticles (DDS NPs) were constructed by absorption of DOX NPs around ABT-199 micelles with an optimal ratio via electrostatic interaction. The shape of DDS NPs was similar to a raspberry, and the size was 112 6 ± 13 4 nm. The encapsulation efficiencies of DOX and ABT-199 in DDS NPs were 90 2 ± 4 3% and 94 7 ± 2 8%, respectively; meanwhile, the drug loadings were 1 5 ± 0 4% and 14 1 ± 1 1%, respectively. After 72 h of dialysis, 95% of ABT-199 remained and less than 50% of DOX was released. In vitro investigation showed that the drugs in DDS NPs maintained the treated effect in three HCC cell lines; moreover, DDS NPs could perform intracellular delivery of dual drugs and exhibited continuous release of the drugs into different targets. Low in vivo toxicity was found after the acute toxicity test. In vivo fluorescent imaging revealed that DDS NPs could efficiently target and accumulate in the tumor tissues and be maintained more than 72 h after intravenous injection. Compared with free drugs, DDS NPs with the same dosages exhibited a more significant antitumor effect in the HCC xenograft mouse model. The results indicated that DDS NPs have great potential in HCC chemotherapy.Tables S1 and S2: CI and dose reduction values for inhibition of BEL-7402, SMMC-7721, and Huh-7 by combining DOX with ABT-263 or ABT-737. The synergistic effects of these two combinations were less than combined DOX with . Especially in ABT-263 combined with DOX, it showed few synergy in three HCC cell lines. Figure S1: WST assay results of BEL-7402, SMMC-7721, and Huh-7 cells treated with dual drugs and DDS NPs. As the result show, the toxicity of empty NPs was almost none, and DDS NPs and free dual drugs have equal antiproliferating effect against three HCC cell lines in vitro. The result indicated that the DDS NPs could perform the synergistic anti-HCC effect of ABT-199 combined with DOX. (Supplementary Materials)

show abstract

“…There are other therapeutics such as siRNA, anti-sense, miRNA, proteins and other therapeutic combinations assembled into a single or multiple formulations that can be considered as a nanomedicine. Such studies were reviewed recently by Huang and colleagues and readers are referred there for additional details [37]. If one excludes those combination therapies that contain drug treatment in conjunction with other modalities such as radio-, immuno-, gene- and photothermal-therapy, the percentage of DcNP studies that have actually progressed to in vivo characterisation would likely be lower than the 8% cited above.…”

Section: Current Status Of Nanoparticle-based Combination Chemotherapymentioning

confidence: 99%

Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook

McConnachie

et al. 2018

Journal of Drug Targeting

View full text Add to dashboard Cite

The concept of nanomedicine is not new. For instance, some nanocrystals and colloidal drug molecules are marketed that improve pharmacokinetic characteristics of single-agent therapeutics. For the past two decades, the number of research publications on single-agent nanoformulations has grown exponentially. However, formulations advancing to pre-clinical and clinical evaluations that lead to therapeutic products has been limited. Chronic diseases such as cancer and HIV/AIDS require drug combinations, not single agents, for durable therapeutic responses. Therefore, development and clinical translation of drug combination nanoformulations could play a significant role in improving human health. Successful translation of promising concepts into pre-clinical and clinical studies requires early considerations of the physical compatibility, pharmacological synergy, as well as pharmaceutical characteristics (e.g. stability, scalability and pharmacokinetics). With this approach and robust manufacturing processes in place, some drug-combination nanoparticles have progressed to non-human primate and human studies. In this article, we discuss the rationale and role of drug-combination nanoparticles, the pre-clinical and clinical research progress made to date and the key challenges for successful clinical translation. Finally, we offer insight to accelerate clinical translation through leveraging robust nanoplatform technologies to enable implementation of personalised and precision medicine.

show abstract

Nanoformulations for combination or cascade anticancer therapy

Cited by 148 publications

References 230 publications

<p>Nanoformulated Bioactive Compounds Derived from Different Natural Products Combat Pancreatic Cancer Cell Proliferation</p>

<p>Nanoformulated Bioactive Compounds Derived from Different Natural Products Combat Pancreatic Cancer Cell Proliferation</p>

Doxorubicin and ABT-199 Coencapsulated Nanocarriers for Targeted Delivery and Synergistic Treatment against Hepatocellular Carcinoma

Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook

Contact Info

Product

Resources

About